It is unclear if tau pathology is substantial enough in PD patients, or whether tau PET is sensitive enough to differentiate more subtle pathology changes, but this type of secondary analysis may be broadly applicable in neurodegenerative disease, if not in living patients, then possibly in post-mortem neuropathological studies. This evidence concerns the gene MAPT and Parkinson disease.